Here, we advance the understanding of how Siglec-sialoglycan interactions on suppressive myeloid cells can shape an immunosuppressive environment via the secretion of inhibitory CCL2 in the context of cancer across different human and murine models. The gene discussed is CCL2; the disease is cancer.